Clinical Trial Update: FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer [Phase 4]

View source ↗

Summary

Phase 4 trial update on FOLFOX chemotherapy combined with Fruquintinib and Serplulimab as first-line conversion therapy for initially unresectable pMMR/MSS colo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Cancer Microsatellite Stable

Drugs mentioned

• FOLFOX chemotherapy (leucovorin/5-fluorouracil/oxaliplatin)
• Fruquintinib (fruquintinib)
• Serplulimab (serplulimab)

Snippet

Sponsor: Ye Xu | Conditions: Colorectal Cancer (Locally Advanced or Metastatic), Colorectal Cancer Microsatellite Stable (MSS) | Phase 4 | Status: NOT_YET_RECRUITING